Glucose-induced insulin secretion in uremia: Effects of aminophylline infusion and glucose loads. To explain mechanisms responsible for derangement of insulin release in uremia, we investigated glucose metabolism through three different tests in 14 patients with end-stage chronic renal failure. These tests were: intravenous glucose tolerance test with 0.33 g/kg of glucose solution (IVGTF); IVGTT with 0.5 glkg of glucose solution (IVGTT2); IVGTT during aminophylline infusion (IVGTT+A). Twelve of the patients had IVGTF repeated after two to four months of thrice-weekly regular hemodialysis (IVGTT3). In each test we measured plasma glucose (G), immunoreactive insulin (IRI) and C-peptide. We also calculated glucose constant decay (K), insulin production (IRI area), insulinogenic index (101), and insulin resistance index (RI). Twenty-nine healthy volunteers formed the normal controls for IVGTT. As compared to controls, during IVGTF uremic patients showed significantly lower values in K, IRI area and 101, and showed a significant RI value increase. During IVGTf2, IRI area values were higher than during IVGTT but IGI and K values were unchanged.
increased significantly as compared to the predialysis period. K increase after hemodialysis correlated directly to lGI increase and inversely to RI changes. 101 increase during IVGTT3 was directly correlated to IGI rise during IVGTT+A. From these data we infer that defective insulin release in uremia is due to a decrease of /3-cell glucose sensitivity rather than to their functional exhaustion. An impaired adenyl cyclase-cAMP system may have an important role in the pathogenesis of this abnormality.
The presence of impaired glucose metabolism in uremic patients has long been recognized [1] [2] [3] . Tissue insensitivity to insulin is the primary cause [4, 5] , but several reports suggest that abnormalities in insulin secretion may have, in some patients, an important role in its pathogenesis [6] [7] [8] [9] [10] . Indeed, after oral or intravenous glucose administration [7, 8] or during hyperglycemic clamp technique [10] , some authors noticed that early insulin response is lower in uremic patients than in controls if compared to the magnitude of pancreatic 13-cell glicidic stimulation or to insulin resistance degree. Moreover, recent studies in vitro [11] confirmed that the initial phase of glucose-induced insulin release is decreased in uremic rats.
glucose stimulation.
To explain mechanisms responsible for this derangement in insulin secretion we investigated in uremic patients the pancreatic /3-cell secretory ability following two stimulations of different intensities (0.33 g/kg and 0.5 glkg intravenous glucose load). Furthermore, in the same patients, we studied changes in glucose-induced insulin release to aminophylline infusion. Aminophylline indeed, through competitive inhibition of phosphodiesterase, raises intracellular cyclic AMP (cAMP) that plays an important role in the modulation of glucose-induced insulin release [13] [14] [15] [16] [17] [18] [19] [20] .
Methods
Fourteen undialyzed patients (8 males and 6 females) between 23 and 75 years of age (49.6 4.2; mean SE), with end-stage chronic renal failure (ESRF; serum creatinine higher than 9 mg/dl), were studied. All of them had negative histories of hepatic and endocrine disorders, negative family histories of diabetes mellitus and no known glucose intolerance before the onset of renal failure. Their primary diseases were: chronic glomerulonephritis in five cases, chronic pyelonephritis in four cases (superimposed to interstitial nephritis in one and to obstructive uropathy in two cases), nephrosclerosis in three cases, and polycystic kidneys in two cases. None of them had hyperkalemia or severe metabolic acidosis. All patients were instructed to have a diet containing at least 250 g/day of carbohydrates during three days before each examination.
Their body weight varied between 90 and 110% of ideal body weight [21] .
In all patients three tests were performed with 24 to 48 hour intervals between each examination: 1) Intravenous glucose tolerance test (IVGTT). After overnight fasting 0.33 g/kg of glucose solution was intravenously injected in two minutes. Blood sampling was made before and 2, 5, 15, 30, 45, 60 minutes after injection using 0.5 mg/mI of EDTA monoiodoacetate as antiglycolytic anticoagulant.
2) IVGTT using 0.5 glkg of glucose solution (IVGTT2).
3) IVGTT during aminophylline intravenous infusion (240 mg rapidly 30 minutes before glucose administration followed by 2 mg/ml/min slow infusion) (JVGTT+A). In this test one more blood sample was taken before aminophylline injection. All data are presented as mean SE. Paired (in the same patients) and unpaired (versus controls) Student's t-tests were used for statistical analysis. Significance of linear correlations was evaluated by Pearson's r and ANOVA table.
Results
Results are summarized in Table I . Compared to controls, during IVGTT uremic patients showed significantly lower K and 0 to IS minute IRI area values. No differences were found between 15 and 60 minute IRI area values in the two groups. However, IGI values in uremic patients were significantly lower both in early and late phase of stimulation.
During IVGTI'2 in uremic patients both 0 to IS minute and 15
to 60 minute IRI area values were higher than during IVGTT, but IGI and K values were unchanged. As shown in Table 2 only one patient (case no.8) exhibited a very low increase (+ 7%) of insulin production after glucose load increase.
During IVGTT+A early and late insulin productions were significantly higher than during IVGTT, both absolutely (IRI areas) and relatively to the magnitude of pancreatic /3-cell glucose stimulation (101). Even K values were higher than in IVG1T but the difference did not reach statistical significance.
Aminophylline infusion alone did not affect 0 and IRI basal In all patients the changes of C-peptide plasma values during the various tests were parallel to changes of IRI plasma values. This indicates that the differences in plasma IRI levels among the various tests were due to different insulin release rates, and not to changes in insulin kinetics.
K increase after hemodialysis (K3) is significantly correlated directly to IGI increases (MGl3) and inversely to RI changes (RI-j. The analysis of multiple linear regression equation is reported in Table 3 . Also, a significant positive relationship was found between IGI3 and 101 increase during IVGTT+A (zIGIA) (Fig. 2) .
Discussion
Our results confirm that ESRF patients show impaired glucose tolerance, insulin resistance, and reduced early insulin release after glucose load [1-10]. However, in our data defective insulin production was present even in the late phase of glycidic stimulation. Indeed, 15 to 60 minute insulin production Fronzo and Alvestrand [9] , after thrice-weekly hemodialysis, found that changes in insulin response after glucose load in uremic patients are inversely correlated to changes in tissue sensitivity. Notably in patients with small changes in insulin resistance, glucose metabolism improvement was due almost entirely to insulin production increase. By these data the authors believe that, in some uremic patients, uremia decreases /3-cell sensitivity to glucose stimulation. Conversely, Carducci Artenisio, Saitta and Bellinghieri [12] believe that insulin production in uremia passes from a phase of compensatory hyperinsulinemia (normal IGI and high insulin plasma values) to a phase of hypoinsulinemia, at first relative (IGI decrease and normal insulin plasma values) and later absolute (both 101 and insulin plasma values decrease), due to progressive functional exhaustion of pancreatic 13-cells.
Our data seem to exclude the hypothesis of functional exhaustion of pancreatic /3-cells in uremia due to attempt to compensate insulin resistance. In such a situation 13-cells should have reached their highest secretion capability and an increment of insulin response should not be possible at all, at least in patients with impaired glucose tolerance. On the contrary, in our investigation we found that glucose loading and phosphodiesterase inhibition, by aminophylline, were able to increase glucose-induced insulin response in ESRF patients. The rise in insulin production during !VGTT+A did not cause a significant improvement of K values in our patients. This may be due to opposite effects of aminophylline on glucose metabolism. Aminophylline not only stimulated release of insulin but also catecholamines that in turn induced glycogenolysis.
The causes of defective insulin production in uremia may be due to a previous phase of hormone release, more exactly to an impaired reception and/or intracellular transmission of glucose stimulus.
IRI area increases without IGI increases in uremic patients during IVGTf2 compared to 1VGT1', may suggest the existence of a reduced pancreatic /3-cell glucose sensitivity, according to
De Fronzo et al [9] . In fact these data show that glucoseinduced insulin release in uremia is correlated to magnitude of glucose stimulation but it is lower than in controls. Furthermore, after hemodialysis treatment 101 goes back to normal values and K improvements are correlated to 101 increases as well to RI decreases. These data indicate that removal of low molecular weight uremic toxins by hemodialysis is able to restore 13-cell secretory ability. There is the possibility that chronic hemodialysis therapy for a period of some months might have improved overall metabolism and increased muscle mass that would in turn provide a net increase in the number of glucose receptor sites and reduce insulin resistance. However, all of our patients but one showed after hemodialysis a K values improvement despite the highly variable RI changes. Also other investigators [I] have shown an immediate effect of dialysis on glucose utilization rates and insulin secretion which has been assumed to result from removal of uremic toxins. The hypothesis of decreased 13-cell glucose sensitivity in uremia is also supported by report of Nakamura et al [Ii] . The authors found that the initial insulin release from columnperifused isolated islets in the presence of glucose is significantly lower in uremic than in control rats without differences in insulin content of islets.
"Uremic toxins" may reduce 13-cell glucose sensitivity by acting on intracellular glucose utilization, which is the main mechanism responsible for insulin release and biosynthesis [13, 14, 16, [22] [23] [24] [25] . Indeed, some authors [26] [27] [28] found a reduction of several enzyme activities of glycolytic pathways in extrapancreatic tissues of uremic patients.
Alternatively uremic toxins may affect the adenyl cyclasecAMP system, which is the main intracellular modulator of glucose-induced insulin release [13] [14] [15] [16] [17] [18] [19] [20] . In our study, we found that the increase in intracellular cAMP by phosphodiesterase inhibition through aminophylline infusion is able to restore the glucose sensitivity of pancreatic 13-cells. We also found a From this investigation we may infer that defective insulin release in ESRF is due to a decrease of 13-cell glucose sensitivity more than to their functional exhaustion. Functional exhaustion of 13-cells may play an adjunctive role in a few patients with very high RI values and/or long-term insulin resistance andlor genetic predisposition. In our study only one patient was incapable of increasing insulin production after an increased glucose load. This patient even showed a reduction of IGI and K after starting maintenance hemodialysis.
In a previous investigation [29] , we also found that insulin resistance-induced 13-cell functional exhaustion is very small in long-term hemodialysis patients.
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